You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 2020223025
Dec 20203607
Jan 20213406
Feb 20211602
Mar 20213004
Apr 20214804
May 2021001
Jun 2021007
Jul 2021008
Aug 2021006
Sep 2021007
Oct 202136025
Nov 202176022
Dec 20217403
Jan 20222003
Feb 20223603
Mar 20225406
Apr 20225008
May 20223401
Jun 20222200
Jul 20221602
Aug 20222002
Sep 20221000
Oct 20222400
Nov 20221201
Dec 20221801
Jan 20231800
Feb 20231000
Mar 20231603
Apr 20231206
May 2023804
Jun 20231600
Jul 2023604
Aug 2023401
Sep 2023200
Oct 20231803
Nov 20231801
Dec 20234001
Jan 20242200
Feb 20241000
Mar 20241202
Apr 20241804
May 20241602
Jun 20243503
Jul 20243201
Aug 20242004
Total12220193